Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

Pfizer (PFE) reported positive results from a Phase 3 study of Talzenna in combination with Xtandi in the treatment of ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $17.4 billion, has announced results from its Phase 3 TALAPRO-2 study which show that a combination of ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at ...

The Food and Drug Administration expanded its approval of one of Pfizer's drugs, Adcetris, allowing it to be used as a treatment for certain types of lymphoma.

A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...